⌕
Zenas Biopharma · ZBIO · Nasdaq
Tenet 29 · Weak
Compare
$27.75−0.64%At closeTenet 29 · Weak
$27.75−0.18 (−0.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Zenas Biopharma (ZBIO) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ZBIO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 17, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease

- New patient and physician surveys reveal differing perspectives on disease burden, treatment goals, and long-term management - WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Co…

ZBIO −0.6% todayRead at source ↗
● Defense WorldNov 11, 2026 · 04:27 ET
Zenas BioPharma, Inc. $ZBIO Shares Acquired by Alps Advisors Inc.

Alps Advisors Inc. increased its position in shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 35.6% during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference

WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and comm…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

- PDUFA target action date of May 27, 2027, following FDA acceptance of obexelimab BLA submission for the treatment of IgG4-RD in August 2026 - - Obexelimab MAA submitted to the EMA for the treatment of IgG4-RD - - New d…

ZBIO −0.6% todayRead at source ↗
● Defense WorldNov 5, 2026 · 01:44 ET
Head-To-Head Review: BioCryst Pharmaceuticals (NASDAQ:BCRX) & Zenas BioPharma (NASDAQ:ZBIO)

BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on th…

ZBIO −0.6% todayRead at source ↗
● MarketBeatOct 30, 2026 · 11:17 ET
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears

Zenas BioPharma NASDAQ: ZBIO outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected la…

ZBIO −0.6% todayRead at source ↗
● Seeking AlphaOct 27, 2026 · 14:10 ET
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript

Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript…

ZBIO −0.6% todayRead at source ↗
● Zacks Investment ResearchOct 23, 2026 · 10:56 ET
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know

The mean of analysts' price targets for Zenas BioPharma, Inc. (ZBIO) points to a 77.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in ra…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireOct 16, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and comm…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireOct 7, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Zenas BioPharma to Host Virtual R&D Event

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and comm…

ZBIO −0.6% todayRead at source ↗
● Seeking AlphaOct 5, 2026 · 05:09 ET
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with pro forma balances cov…

ZBIO −0.6% todayRead at source ↗
● Seeking AlphaSep 30, 2026 · 00:03 ET
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireSep 22, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026

– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireSep 18, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and com…

ZBIO −0.6% todayRead at source ↗
● Seeking AlphaSep 14, 2026 · 21:01 ET
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

ZBIO −0.6% todayRead at source ↗
● Defense WorldSep 10, 2026 · 03:45 ET
Analyzing United Therapeutics (NASDAQ:UTHR) and Zenas BioPharma (NASDAQ:ZBIO)

United Therapeutics (NASDAQ: UTHR - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the …

ZBIO −0.6% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 23:47 ET
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and com…

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and com…

ZBIO −0.6% todayRead at source ↗
● Defense WorldAug 26, 2026 · 04:01 ET
Bank of America Corp DE Purchases 341,187 Shares of Zenas BioPharma, Inc. $ZBIO

Bank of America Corp DE boosted its position in shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 723.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The …

ZBIO −0.6% todayRead at source ↗
● GlobeNewsWireAug 18, 2026 · 16:15 ET
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and comm…

ZBIO −0.6% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just ZBIO · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.